{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1259.9","meta":{"versionId":"5","lastUpdated":"2023-08-17T01:00:54.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"One Medical Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2023-08-17"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-08-17"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1259.9"}],"version":"20230817","name":"IgEAgonistsPrescribable","title":"IgE Agonists, prescribable","status":"active","date":"2023-08-17T01:00:54-04:00","publisher":"One Medical Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this value set is to represent concepts for IgE Agonists appropriate for asthma control.),(Data Element Scope: This value set may be used to represent a Medication.),(Inclusion Criteria: Includes concepts that describe a medication specific to prescribable SBD/SCD TTYs for Omalizumab.),(Exclusion Criteria: None)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"1657209","display":"omalizumab 150 MG Injection"},{"code":"1657212","display":"omalizumab 150 MG Injection [Xolair]"}]}]},"expansion":{"identifier":"urn:uuid:71e0e36d-3224-47fd-a19c-7908a457192a","timestamp":"2023-12-11T00:43:52-05:00","total":2,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657209","display":"omalizumab 150 MG Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657212","display":"omalizumab 150 MG Injection [Xolair]"}]}}